University of Nebraska Medical Center

DigitalCommons@UNMC
Journal Articles: Genetics, Cell Biology &
Anatomy

Genetics, Cell Biology & Anatomy

10-30-2009

Accurate molecular classification of cancer using simple rules.
Xiaosheng Wang
University of Nebraska Medical Center, xiaosheng.wang@unmc.edu

Osamu Gotoh
Kyoto University

Follow this and additional works at: https://digitalcommons.unmc.edu/com_gcba_articles
Part of the Medical Anatomy Commons, Medical Cell Biology Commons, and the Medical Genetics
Commons

Recommended Citation
Wang, Xiaosheng and Gotoh, Osamu, "Accurate molecular classification of cancer using simple rules."
(2009). Journal Articles: Genetics, Cell Biology & Anatomy. 13.
https://digitalcommons.unmc.edu/com_gcba_articles/13

This Article is brought to you for free and open access by the Genetics, Cell Biology & Anatomy at
DigitalCommons@UNMC. It has been accepted for inclusion in Journal Articles: Genetics, Cell Biology & Anatomy
by an authorized administrator of DigitalCommons@UNMC. For more information, please contact
digitalcommons@unmc.edu.

B M C M ed i cal Gen o m i cs

Bio M ed Central

Research article

Open Ac c ess

A ccur at e m olecular classificat ion of cancer using sim ple r ules
Xiaosheng Wang* 1 an d Osam u Gotoh 1,2
Address: 1 Departm en t of Intelligence Scien ce and Techn ology, Graduate Sch ool of In form atics, Kyoto Un iversity, Kyoto 606-8501, Japan an d
2 Nation al In stitute of Advan ced In dustrial Science an d Techn ology, Com putation al Biology Research Center, Tokyo 135-0064, Japan
Em ail: Xiaoshen g Wan g* - david@gen om e.ist.i.kyoto-u.ac.jp; O sam u Gotoh - o.gotoh @i.kyoto-u.ac.jp
* Correspondin g auth or

Published: 30 October 2009
BMC Medical Genomics 2009, 2:64

doi:10.1186/1755-8794-2-64

Received: 5 February 2009
Accepted: 30 October 2009

This article is available from: http://www.biomedcentral.com/1755-8794/2/64
© 2009 Wang and Gotoh; licensee BioMed Central Ltd.
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0),
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

A bst r act
Backgr ound: One intractable problem with using microarray data analysis for cancer classification
is how to reduce the extremely high-dimensionality gene feature data to remove the effects of
noise. Feature selection is often used to address this problem by selecting informative genes from
among thousands or tens of thousands of genes. However, most of the existing methods of
microarray-based cancer classification utilize too many genes to achieve accurate classification,
which often hampers the interpretability of the models. For a better understanding of the
classification results, it is desirable to develop simpler rule-based models with as few marker genes
as possible.
Met hods: W e screened a small number of informative single genes and gene pairs on the basis of
their depended degrees proposed in rough sets. Applying the decision rules induced by the selected
genes or gene pairs, we constructed cancer classifiers. W e tested the efficacy of the classifiers by
leave-one-out cross-validation (LOOCV) of training sets and classification of independent test sets.
Result s: W e applied our methods to five cancerous gene expression datasets: leukemia (acute
lymphoblastic leukemia [ALL] vs. acute myeloid leukemia [AML]), lung cancer, prostate cancer,
breast cancer, and leukemia (ALL vs. mixed-lineage leukemia [MLL] vs. AML). Accurate
classification outcomes were obtained by utilizing just one or two genes. Some genes that
correlated closely with the pathogenesis of relevant cancers were identified. In terms of both
classification performance and algorithm simplicity, our approach outperformed or at least
matched existing methods.
Conclusion: In cancerous gene expression datasets, a small number of genes, even one or two if
selected correctly, is capable of achieving an ideal cancer classification effect. This finding also means
that very simple rules may perform well for cancerous class prediction.

Backgr ound
Rapid advances in gene expression m icroarray techn ology
h ave enabled the sim ultan eous m easurem en t of the
expression levels of tens of th ousands of gen es in a single
experimen t [1]. By m easuring gen e expression levels
related to multiple in dividuals and multiple tissue or

tum or sam ples, investigators can discover molecular
markers to be used for cancer diagnosis, prognosis, and
prediction. Many researchers have explored the use of
microarray technology to build cancer diagnosis, prognosis, and prediction classifiers, since the pioneering work of
Golub et al. in applying gene expression monitoring by
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DNA m icroarray to cancer classification [2]. However, on e
intractable problem with using m icroarray data analysis
to create can cer classifiers is how to reduce th e exceedin gly
h igh -dim en sion al gen e expression data, wh ich con tain a
large amount of noise. On th e other h and, com pared with
the m easured quantities of gene expression levels in
experimen ts, the num bers of sam ples are severely lim ited.
Th is brings about two com putation al challenges: com putational cost and classification accuracy. To ach ieve efficien t an d accurate classification , it is n atural for
researchers to investigate feature selection; i.e., gen e filtering [3]. However, on e serious drawback of most existin g
m eth ods is that too m an y gen es are ultim ately selected for
the classification of cancer, th ereby ham pering th e in terpretability of th e models. In fact, it is n ot easy to gauge
wh ich gen e is essential in determ in in g a can cerous class if
accurate classification is obtained based on a large cluster
of genes.
In parallel with feature selection , classifier con struction is
an im portan t topic in th is field. In m achin e learn in g and
data m ining, the m eth ods of gen eratin g classifiers include
unsupervised and supervised approaches. The latter is further classified into two categories: "black-box" and
"wh ite-box" m odels. Th e "black-box" m odels, such as
support vector mach ines (SVMs), discrim in ant analysis
(DA), artificial neural networks (ANNs), gen etic algorithm s (GAs), n a¨ve Bayes (NB), an d k-nearest neigh bors
(k-NNs), address classification problem s with out any
knowledge-based explanation rules. In contrast, the
"wh ite-box" models, such as Decision Trees [4], Rough
Sets [5], and em ergin g pattern s (EPs) [6], often implem ent classification by giving "IF-THEN"-like rules. The
"wh ite-box" models are sometimes m ore welcom ed by
biologists an d clin icians because they are easily understood.
Man y in vestigators have utilized the rule-based
approaches (i.e., "wh ite-box" m odels) to produce cancer
classifiers [6-13]. In general, these classifiers in volve few
gen es, whereas they exhibit efficient prediction perform an ce. In [6], th e authors proposed on e m eth od of identifyin g good diagn ostic gene groups from gene expression
profiles usin g th e con cept of EPs. Th e authors sought to
find the gen e groups whose frequen cy of patterns changed
significantly between two classes of cells. They then used
the rules arising from these pattern s to construct cancer
classifiers. Th eir classifiers were uncom plicated, as they
m erely contain ed th e rules involvin g a few genes. In [11],
decision tree algorithm s in volvin g single C4.5, Bagging,
an d AdaBoost decision trees were applied to classify gene
expression datasets. In essen ce, a decision tree is a rulebased classifier. The classifier screen s the inform ative features to build decision trees based on th e in form ation
en tropy concept. Subsequen tly, rules are derived from the
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trees. Because decision tree algorithm s com m only conduct pruning of the trees to rem ove unnecessary features,
the derived rules generally involve only a small number of
features. In [13], the authors proposed the use of highranked association rule groups to construct cancer classifiers instead of utilizing all of the m ined association rules,
which com m only involves excessive num bers of redundant rules.
Som e investigators have addressed the problem of using
pairs of genes to conduct cancer classification. In [14], the
authors classified gene expression profiles using a com parison-based approach, the "top-scoring pair(s)," called
the TSP classifier. The authors attem pted to predict classes
by comparing the expression levels of a single pair of
genes, chosen based on a simple m easure of class discrim ination. In [15], the authors investigated the use of gene
pairs for classification. They screened the gene pairs that
had m arked differences in average expression levels
between the tumor types in the training set. The gene pairs
were then applied to classify test sets.
Rough sets, a data-analysis method originally proposed by
Pawlak in the early 1980s [5], has evolved into a widely
accepted m achine-learning and data-m ining m ethod [16].
In [7-10], rough sets was applied for cancer classification
and prediction based on an attribute reduction approach.
In [17], we proposed a rough sets-based soft computing
method to conduct cancer classification using single genes
or gene pairs. In this article, we also explore the use of single genes and gene pairs in constructing cancer classifiers;
however, in contrast to [17], we first aim ed to use the concept of canonical depended degree, as proposed in rough
sets for gene selection. In the cases that this approach was
unsuccessful, we considered utilizing the α depended
degree standard suggested in [17] for gene selection. In
this work, the α depended degree was employed for a portion of the datasets. In addition, unlike the other rough
sets-based m ethods, we did not carry out attribute reduction for gene selection. Instead, we first im plemen ted feature ranking according to the depended degree or α
depended degree of attributes, and then selected th e topranked genes to create classifiers so as to avoid expensive
com putation for attribute reduction. Moreover, we m ade
use of the decision rules induced by the chosen genes to
build classifiers, whereas existing rough sets-based methods only utilized rough sets for gene selection, and the
classifier constructions depended upon other machinelearning algorithms such as SVMs, ANNs, GAs, NB, and kNNs [7-10].
We tested the m ethods in the five publicly available gene
expression datasets: Leukem ia 1 (ALL vs. AML), Lung Cancer, Prostate Cancer, Breast Cancer, and Leukemia 2 (ALL
vs. MLL vs. AML), which can be downloaded from the
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Ken t Ridge Bio-m edical Data Set Repository http://
datam .i2r.a-star.edu.sg/datasets/krbd/. We com pared our
results with th e fin din gs of previous studies. Furth erm ore,
we exam ined an d analyzed th e biological relevance of the
selected gen es.

Met hods

Rough sets
In rough sets, an equivalen ce relation on U is referred to
as one knowledge, an d a fam ily of equivalen ce relation s is
referred to as a knowledge base on U. In reality, we are often
faced with a large amount of ill-defined data, and we wan t
to learn about them based on pre-existin g knowledge.
However, m ost of these data can not be precisely defined
based on pre-existin g knowledge, as they in corporate both
defin ite and vague com pon ents. In [5], Pawlak describes
the defin ite parts using th e concept of positive region .

Defin itio n 1 Let U be a un iverse of discourse, X ⊆ U, an d
R is an equivalence relation on U. U/R represents the set
of th e equivalen ce class of U induced by R. Th e positive
region of X on R in U is defined as pos(R, X) = ∪ {Y ∈ U/R
| Y ⊆ X}[5].
Th e decision table is th e data form studied by rough sets.
On e decision table can be represen ted as S = (U, A = C ∪
D), wh ere U is the set of sam ples, C is the con dition
attribute set, and D is th e decision attribute set. Without
loss of generality, h ereafter we assume D is a sin gle-elem ent set, and we call D the decision attribute. A can be
viewed as a kn owledge base in S, as each attribute or
attribute subset can in duce an equivalen ce relation on U.
In th e decision table, if we designate Ia as the fun ction
m apping a m em ber (sam ple) of U to the value of the
m em ber on th e attribute a (a ∈ A), th en th e equivalence
relation R(A') in duced by th e attribute subset A' ⊆ A is
defin ed as: for ∀x, y ∈ U, xR(A')y, if an d on ly if Ia (x) = Ia(y)
for each a ∈ A'.
For the cancer classification problem, every collected set
of m icroarray data can be represen ted as a decision table
in th e form of Table 1. In the microarray data decision

table, there are m sam ples and n genes. Every sam ple is
assigned to one class label. The expression level of gene y
in sam ple x is represented by g(x, y).
In rough sets, the degree of dependency of a set of attributes
Q on another set of attributes P is denoted by γP(Q) and is
defined as

g P ( Q) =
Where | POS P ( Q ) | =|

| POS P ( Q )|
,
|U |

∪

pos( P , X) | represents the

X∈U / R( Q )

size of the union of the lower approxim ation of each
equivalence class in U/R(Q) on P in U, and | U| represents
the size of U (set of samples).
If Q is the decision attribute D, and P is a subset of condition attributes, then γP(D) represents the depended degree
of the condition attribute subset P by the decision
attribute D; that is, to what degree P can discrim inate the
distinct classes of D. In this sense, γP(D) reflects the classification power of the subset P of attributes. The greater is
γP(D), the stronger the classification ability P is inclined to
possess. We chose the measure of the depended degree of
condition attributes by class attributes as the basis for
selecting inform ative genes.
In contrast to other correlation-based feature selection
standards such as t-score, the depended degree can be calculated only when the attribute values are discrete. Thus, for
the studied microarray datasets, the discretization of gene
expression values is an essential step. Indeed, the discretization will bring about several advantages. First, som e
unim portant genes will be found im m ediately after the
discretization. When the discretized expression values of a
gene are identical am ong all of the sam ples, we view the
gene as being insignificant because distinct classes cannot
be separated according to the gene's expression values.
Second, when gene expression values are reduced to dis-

T able 1: Micr oar r ay dat a decision t able

Sam ples
Gene 1

Condit ion at t r ibut es (genes)
Gene 2
...

Gene n

Decision at t r ibut es (classes)
Class label

1

g(1,1)

g(1,2)

...

g(1, n)

Class (1)

2

g(2,1)

g(2,2)

...

g(2, n)

Class (2)

...

...

...

...

...

...

m

g(m,1)

g(m,2)

...

g(m, n)

Class (m)
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crete states, the rules form ed by th e genes can be described
n aturally via the discretized data.
However, for som e datasets it is difficult to detect th e discrim inative features based on th e depen ded degree
because of its excessively rigid definition . In this case, we
em ployed th e α depended degree proposed in [17] as the
basis for ch oosing gen es. The α depended degree of an
attribute subset P by th e decision attribute D is defin ed as

g P ( D, a ) =

| POS P ( D ,a )|
|U |

| POS P ( D , a ) | =|

∪

,

wh ere

0

≤

α

≤

1,

pos( P , X, a ) | and pos(P, X, α ) =

X∈U / R( D )

∪{Y ∈ U/R(P) | | Y ∩ X| /| Y| ≥ α } [17]. In fact, as in dicated
in [17], th e depen ded degree is a specific case of the α
depended degree when α = 1. In th e case th at th e
depended degree was largely in effective as a basis on
wh ich to screen features, we employed the α (0.7 ≤ α < 1)
depended degree.
Inducing decision rules that are h idin g in decision tables
is one of th e key tasks of rough sets, wh ich is also an essential procedure of our classifier con struction . O ne decision
rule in th e form of "A ⇒ B" indicates that "if A, th en B,"
wh ere A is the description of condition attributes and B
the description of decision attributes. Th e confidence of a
decision rule A ∧ B is defin ed as follows:
support ( A∧B)

con fidence ( A ⇒ B) = support ( A) , where support(A)
denotes the proportion of th e samples satisfying A an d
wh ere support(A ∧ B) denotes th e proportion of th e sam ples satisfyin g A an d B simultan eously. The confiden ce of
a decision rule indicates the reliability of the rule. If a decision rule had 100% confidence, we called it a consistent
decision rule. It is eviden t th at if γP(D) equals 1, P ⇒ D
m ust be a con sistent decision rule. In con trast, γP(D, α ) =
1 does not m ean that P ⇒ D m ust be a consistent decision
rule.
To en sure th e reliability of th e classification rules, we
chose on ly the genes or gen e pairs with γP(D) or γP(D, α )
equal to 1 when formin g decision rules. Suppose g is one
of th e selected gen es an d U is th e sam ple set. U/R(g) =
{c1 (g), c2 (g), ..., cn (g)} represents the set of the equivalence class of samples in duced by R(g). Two sam ples, s1
an d s2 , belong to th e sam e equivalen ce class of U/R(g) if
an d only if th ey h ave th e sam e value on g. In addition , we
represented the set of the equivalen ce class of sam ples

induced by R(D) as U/R(D) = {d 1 (D), d 2 (D), ..., d m (D)},
where D is the decision attribute. Likewise, two samples,
s1 and s2 , belong to the sam e equivalence class of U/R(D)
if and only if they have the sam e value on D. For each ci(g)
(i = 1, 2, ..., n), if there exists som e d j(D) (j ∈ {1, 2, ...,
m}), satisfying ci(g) ⊆ d j(D) in light of the depended
degree or | ci(g) ∩ d j(D)| /| ci(g)| ≥ α in light of the α
depended degree, we then generated the following classification rule: A(ci(g)) ⇒ B(d j(D)), where A(ci(g)) is the
form ula describing the sam ple set ci(g) by the g value, and
B(d j(D)) is the form ula describing the sam ple set d j(D) by
the class value. We used the sam e strategy to construct
classification rules for gene pairs.
In the case of the depended degree, each employed classification rule was the consistent decision rule. However, in
the case of the α depended degree, the classification rules
may not have been consistent, yet the confidence of every
classification rule m ust be no less than α , as proven in
[17]. Hence, if we specified a large enough α threshold,
the confidence of classification rules would have been sufficiently high.
Datasets
Leukemia dataset 1 (ALL vs. AML)
The first dataset we analyzed was the well-known leukemia data studied by Golub et al. [2], which has been
explored widely by many researchers. In this dataset, there
are 72 observations, each of which is described by the
gene expression levels of 7129 genes and a class attribute
with two distinct labels: AML vs. ALL. The 72 observations
are divided into a training set with 38 sam ples (27 ALL, 11
AML) and a test set with 34 samples (20 ALL, 14 AML).
Lung Cancer dataset
The Lung Cancer dataset is a classification of m alignant
pleural m esotheliom a (MPM) vs. adenocarcinom a
(ADCA) of the lung [15], and consists of 181 tissue sam ples (31 MPM, 150 ADCA). The training set contains 32
of the sam ples (16 MPM vs. 16 ADCA); the rem aining 149
sam ples are used for testing. Each sam ple is described by
12,533 genes.
Prostate Cancer dataset
The Prostate Cancer dataset is concerned with prostate
tum or vs. norm al classification. The training set contains
52 prostate tumor samples and 50 non-tumor prostate
sam ples [18]; the total num ber of genes is 12,600. Two
classes are denoted as "Tumor" and "Norm al." The test set
sam ples were from a different experim ent and have a
nearly 10-fold difference in overall m icroarray intensity
com pared with the training data. We m ade use of the test
set provided by Kent Ridge Bio-m edical Data Set Repository, which includes 25 tumor and 9 norm al samples.
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Breast Cancer dataset
Th is dataset is con cerned with th e prediction of patient
outcom e for breast can cer [19]. The training set con tain s
78 patien t sam ples, 34 of wh ich are from patien ts who
h ad developed distan t m etastases within 5 years
("relapse"); th e rem aining 44 sam ples are from patien ts
wh o remained h ealthy from the disease for an interval of
at least 5 years after initial diagn osis ("non -relapse").
Th ere are 12 relapse and 7 non-relapse sam ples in th e test
set, and the n umber of gen es is 24,481.
Leukemia dataset 2 (ALL vs. MLL vs. AML)
Th is dataset is about subtype prediction for leukemia [20].
Th e training set contain s 57 sam ples (20 ALL, 17 MLL,
an d 20 AML), wh ile the testin g set con tains 15 sam ples (4
ALL, 3 MLL, and 8 AML). The num ber of gen es is 12,582.

Th e gen e num ber, class, train ing sample n umber an d test
sample n um ber con tained in the five datasets are listed in
Table 2.
Dat a preprocessing
Normalization of attributes value
Because the train ing set samples and the test set sam ples
in the prostate cancer dataset are from two differen t experim en ts, and because discrepan cies in microarray in tensity
exist between the two sets of samples, we n ormalized both
the train ing set and the test set. Suppose th at th e original
expression level of gen e y in sam ple x is g(x, y). Th en, the
n ormalized
value
of
g(x,
y)
is
g ( x, y) −(max g (• , y) + min g (• , y))/ 2
(max g (• , y) −min g (• , y))/ 2

, where max g( , y) an d m in

g( , y) represent th e m aximum and th e m inimum expression levels of gene y in all of th e samples, respectively.
After norm alization, all of th e expression levels of the
gen es lie with in th e interval [-1, 1]. As a result, we can
apply the rules induced in th e train in g set to the test set.
Because the train ing set samples an d the test set sam ples
in th e oth er datasets are from the sam e experiments, we
chose n ot to norm alize these data to avoid an y loss of
inform ation .

Discretization of decision tables
Because rough sets is suitable for handling discrete
attributes, we needed to first discretize the training set
decision tables. We used the entropy-based discretization
method, as first proposed by Fayyad et al. [21]. Th is algorithm recursively applies an entropy m inim ization h euristic to discretize the continuous-valued attributes. The stop
of the recursive step for this algorithm depends on the
minim um description length (MDL) principle. We im plemented the discretization in the Weka package [22]. After
the discretization, the majority of attributes contained at
most two distinct values, while a sm all num ber of
attributes contained three or four distinct values. We executed our learning algorithm in the discretized decision
tables.
Feature selection, classifier construction, and validation
For the Leukem ia 1 and Lung Cancer datasets, we con ducted feature selection by the depended degree, wh ile for
the Prostate Cancer, Breast Cancer and Leukemia 2 datasets, we implem ented feature selection by the α depended
degree. For each dataset, we em ployed the LOOCV
approach for the training set to identify high class-discrim ination genes or gene pairs. That is, in the training set
containing n sam ples, each sam ple is left out in turn, and
the learning algorithm is trained on the rem aining n-1
sam ples. Then, the training result is tested on the left-out
sam ple. The final estim ate is the average of n test results.
We em phasize that only the single genes or gene pairs
chosen by all of the leave-one-out training sets are used
for LOOCV. In other words, when the depended degree
standard is utilized, only those genes or gene pairs with a
100% depended degree in all leave-one-out training sets
are selected; when the α depended degree standard is
used, only the genes and gene pairs satisfying γP(D, α ) = 1
in all of the leave-one-out training sets are chosen. According to the results of LOOCV, we finally determ ined the
inform ative genes or gene pairs. Applying the classification rules induced by the single genes or gene pairs in the
entire training set to classify the independent test set, we
further verified their classification performance.

T able 2: Sum m ar y of t he five gene expr ession dat aset s

Dat aset

# Or iginal genes

Class

# Tr aining sam ples

# Test sam ples

Leukemia 1

7129

ALL/AML

38 (27/11)

34 (20/14)

Lung Cancer

12533

MPM/ADCA

32 (16/16)

149 (15/134)

Prostate Cancer

12600

Tumor/Normal

102 (52/50)

34 (25/9)

Breast Cancer

24481

relapse/non-relapse

78 (34/44)

19 (12/7)

Leukemia 2

12582

ALL/MLL/AML

57 (20/17/20)

15 (4/3/8)

Page 5 of 23
(page number not for citation purposes)

BMC Medical Genomics 2009, 2:64

http://www.biomedcentral.com/1755-8794/2/64

Result s

Classification results
Leukemia dataset 1
In this dataset, we first selected in form ative sin gle genes.
Am ong th e 7129 genes, only gene #4847 had a 100%
depended degree in all leave-one-out training sets. We
denoted the expression level of gene x by g(x). The decision rules induced by gen e #4847 in every leave-on e-out
trainin g set are of th e following form: if g(#4847) > t, then
AML; if g(#4847) ≤ t, then ALL, where t is equal or close
to 994. One can apply the decision rules to classify the
left-out sam ple. Th e final LOOCV accuracy resultin g from
the gen e was 97.4%, with 37 of the 38 sam ples classified
correctly, wh erein all of th e 27 ALL sam ples were classified
correctly, and on e AML sam ple was misclassified. Subsequently, we exam ined th e depended degree of th e gene in
the wh ole trainin g set of 38 samples. As expected, th e gene
h ad a 100% depen ded degree in the train in g set. The two
con sistent decision rules generated by th is gene were as
follows: if g(#4847) > 994, then AML; if g(#4847) ≤ 994,
then ALL. One can use th e above rules to classify the in dependen t test set with 91.2% classification accuracy.
Am ong the 34 samples, 31 were classified correctly an d 3
were classified incorrectly: 2 ALL sam ples were m isclassi-

fied into AML, and 1 ALL sam ple was misclassified into
AML.
Next, we searched for inform ative gene pairs. Because
there are 7129 genes, the com bination num ber would be
huge if all were taken into account. Therefore, for each
leave-one-out training set, only the genes with m ore than
18/37 depended degree were considered in form ing gene
pairs (excluding the aforem entioned gene #4847). As a
result, 350 gene pairs were found to possess a 100%
depended degree in all leave-one-out training sets. Every
gene pair was capable of inducing four consistent decision
rules, which were used for classification. We set the
threshold of LOOCV accuracy such that at least 35 of the
38 sam ples were classified correctly. Accordingly, 347
gene pairs satisfied the condition. Likewise, using the
decision rules induced by the gene pairs in the whole
training set to classify the test set, we detected 13 gene
pairs with no less than 32 test samples classified correctly
(at most, 2 errors). Table 3 lists data for these 13 pairs of
genes. In this table, the classification results regarding
LOOCV and the test set are shown in terms of both the
num ber of correctly classified sam ples and accuracy. The

T able 3: T hir t een gene pair s wit h high classificat ion accur acy in t he Leukem ia dat aset 1

1st - 2nd Pr obe ID

Classificat ion r esult s in LOOCV

Classificat ion r esult s in t he t est set

# Cor r ect ly classified sam ples

A ccur acy (%)

# Cor r ect ly classified sam ples

A ccur acy (%)

U46499_at - M92287_at

35 (26/9)

92.11 (96.30/81.82)

33 (20/13)

97.06 (100/92.86)

U46499_at - M12959_s_at

36 (27/9)

94.74 (100/81.82)

34 (20/14)

100 (100/100)

U46499_at - D63880_at

36 (27/9)

94.74 (100/81.82)

33 (20/13)

97.06 (100/92.86)

U46499_at - S50223_at

37 (27/10)

97.37 (100/90.91)

33 (19/14)

97.06 (95/100)

U46499_at - Z15115_at

35 (26/9)

92.11(96.30/81.82)

33 (20/13)

97.06 (100/92.86)

L09209_s_at - M92287_at

37 (27/10)

97.37 (100/90.91)

33 (20/13)

97.06 (100/92.86)

L09209_s_at - S50223_at

37 (27/10)

97.37 (100/90.91)

33 (19/14)

97.06 (95/100)

X61587_at - M92287_at

36 (26/10)

94.74 (96.30/90.91)

33 (20/13)

97.06 (100/92.86)

X61587_at - M12959_s_at

37 (27/10)

97.37 (100/90.91)

33 (19/14)

97.06 (95/100)

L09209_s_at - D63880_at

37 (27/10)

97.37 (100/90.91)

32 (19/13)

94.12 (95/92.86)

U05259_rna1_at - M92287_at

36 (26/10)

94.74 (96.30/90.91)

32 (20/12)

94.12 (100/100)

L09209_s_at - X59417_at

37 (27/10)

97.37 (100/90.91)

32 (19/13)

94.12 (95/92.86)

L09209_s_at - Z15115_at

37 (27/10)

97.37 (100/90.91)

32 (19/13)

94.12 (95/92.86)
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results with respect to every class are presented in parentheses, an d the optim al results are form atted in boldface.
Am ong the 13 gene pairs, th e com bin ation #3252-#6167
possessed 100% classification accuracy on the test set. The
decision rules produced by th e gene pair were as follows:
if g(#3252) ≤ 156.5 an d g(#6167) > 820.5, then ALL;
if g(#3252) ≤ 156.5 and g(#6167) ≤ 820.5, th en ALL;
if g(#3252) > 156.5 an d g(#6167) > 820.5, then ALL;
if g(#3252) > 156.5 and g(#6167) ≤ 820.5, then
AML.
Th e above rules were then simplified into th ree equivalen t
rules:
if g(#3252) ≤ 156.5, th en ALL;
if g(#6167) > 820.5, th en ALL;
if g(#3252) > 156.5 and g(#6167) ≤ 820.5, then
AML.
Th ese th ree rules are fairly sim ple and easily understood.
Using these rules, we classified th e test set with out any
errors. Th e rules derived from the other 12 gen e pairs are
provided in the Additional file 1, an d we also provide
inform ation on th e top 87 genes in the training set with
depended degrees of no less than 0.5 in the Addition al file
2.
Lung Cancer dataset
Th is dataset contain ed 16 gen es with a 100% depended
degree in all of the 32 leave-one-out training sets. Th e
LOOCV accuracy of the 16 gen es was between 93.75%
an d 100%. Nam ely, th e number of correctly classified
samples ran ged from 30 to 32. In th e train ing set, each of
the 16 gen es had a 100% depended degree. These observation s indicate that each single gene am ong th e 16 genes
was likely to h ave high class-discriminative power in the
training set. Using th e rules gen erated by th ese single
gen es, we exam in ed th e test set. As expected, these genes
showed high classification performan ce, with classification accuracy ran ging from 79% to 97%. Th e classification
results are presen ted in Table 4, which sh ows that some of
the genes in the Lun g Can cer dataset, such as gene
37716_at, have im pressive classification performan ce.
Th e rules induced by gen e 37716_at were the following: if
g(37716_at) > 197.75, th en mesoth eliom a; if
g(37716_at) ≤ 197.75, th en ADCA. Usin g th ese two rules,
we could classify th e test set with 97% accuracy. Th e rules
produced by the 16 genes are provided in th e Addition al
file 3. From th ese rules, we suspected th at 2047_s_at,

http://www.biomedcentral.com/1755-8794/2/64

2266_s_at, 32046_at, 33245_at, 41286_at, 41402_at,
575_s_at, and 988_at have higher expression levels in
ADCA, while the others have higher expression levels in
mesotheliom a.
If m ore than one gene is considered when developing
rules, higher classification accuracy should be achieved.
Therefore, we carried out further classification tests using
gene pairs. As before, we tried to find the gene pairs with
high LOOCV accuracy. To avoid com bination explosion ,
to constitute gene pairs we only selected genes with m ore
than 12/31 and less than 100% depended degree in all 32
leave-one-out training sets. Furtherm ore, to avoid intricate classification rules produced by gene pairs, we
excluded genes with more than two distinct discretized
values. Accordingly, we found 82 gene pairs with a 100%
depended degree in all 32 leave-one-out training sets.
Am ong them , 25 pairs possessed 100% LOOCV accuracy.
These pairs also had com paratively strong classification
power in the test set. Their classification accuracy was
between 71.14% and 96.64%; 21 pairs showed accuracy
exceeding 80%, and nine pairs had accuracy exceedin g
90%. Data for these 25 gene pairs are listed in Table 5. The
classification rules induced by these pairs are presented in
the Additional file 3.
To observe the relationship between the depended
degrees of single genes and the classification accuracy of
gene pairs, we carried out another experiment. In the discretized training set, we first excluded the genes with
depended degrees 0 and 100%, as well as the genes with
above two distinct values. As a result, there were 1428
genes left for pair com bination. We set the threshold
num ber of correctly classified sam ples as 148; that is, we
searched for the gene pairs by which the test set are classified with at m ost one error. In addition, we set an other
threshold k, and required that the sizes of the positive
regions caused by the selected genes m ust exceed k, with k
varying from 13 to 0. When k equals 13, 61 genes are
selected, and 743 pair com binations have 100%
depended degree. Using the rules derived from each of the
743 gene pairs to classify the test set, we detected 4 com binations with 148 samples classified correctly. Wh en k
was 12, 11, and 10, only the same four com binations were
found. When k decreased to 9 and 8, five and seven com binations were found, respectively. At lower values, no
more combinations were found to classify 148 sam ples or
more correctly, even when k was reduced to 0, and the
selected gene num ber is 1428 accompanied by 33,390
com binations with a 100% depended degree. The results
indicate that combinations between genes with higher
depended degrees are m ore likely to produce accurate
classification.
To explore whether the com binations between the genes
with 100% depended degrees and other genes with lower
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T able 4: Sixt een genes wit h high classificat ion accur acy in t he Lung Cancer dat aset

Pr obe ID

Classificat ion r esult s in LOOCV

Classificat ion r esult s in t he t est set

# Cor r ect ly classified sam ples

A ccur acy(%)

# Cor r ect ly classified sam ples

A ccur acy(%)

2047_s_at

30 (15/15)

93.75 (93.75/93.75)

122 (11/111)

81.88 (73.33/82.84)

266_s_at

32 (16/16)

100 (100/100)

129 (13/116)

86.58 (86.67/86.57)

32046_at

30 (15/15)

93.75 (93.75/93.75)

133 (12/121)

89.26 (80/90.30)

32551_at

31 (15/16)

96.88 (93.75/100)

134 (14/120)

89.93 (93.33/89.55)

33245_at

30 (15/15)

93.75 (93.75/93.75)

137 (14/123)

91.95 (93.33/91.79)

33833_at

32 (16/16)

100 (100/100)

139 (13/126)

93.29 (86.67/94.03)

35330_at

31 (15/16)

96.88 (93.75/100)

118 (14/104)

79.19 (93.33/77.61)

36533_at

30 (15/15)

93.75 (93.75/93.75)

141 (13/128)

94.64 (86.67/95.52)

37205_at

30 (15/15)

93.75 (93.75/93.75)

135 (12/123)

90.60 (80/91.79)

37716_at

30 (15/15)

93.75 (93.75/93.75)

145 (11/134)

97.32 (73.33/100)

39795_at

31 (16/15)

96.88 (100/93.75)

135 (14/121)

90.60 (93.33/90.30)

40936_at

31 (15/16)

96.88 (93.75/100)

140 (12/128)

93.96 (80/95.52)

41286_at

30 (15/15)

93.75 (93.75/93.75)

121 (13/108)

81.21 (86.67/80.60)

41402_at

31 (16/15)

96.88 (100/93.75)

123 (13/110)

82.55 (86.67/82.09)

575_s_at

32 (16/16)

100 (100/100)

141 (14/127)

94.64 (93.33/94.78)

988_at

30 (15/15)

93.75 (93.75/93.75)

132 (13/119)

88.59 (86.67/88.81)

depended degrees would yield m ore gen e pairs h avin g no
less than 148 samples classified correctly, we added th e 16
gen es with a 100% depen ded degree to the 1428 genes
an d repeated th e above experim en t. Surprisin gly, the
results were exactly the sam e as those of the first experim ent; i.e., n o new gene pair was found. Th is fin ding indicates that to obtain perfect classification perform an ce by
com bin ed genes, alth ough th e class-discrim in ation ability
of individual genes is im portan t, th e m utual in form ation
com plem en t between individual gen es m ight also be crucial. Additional details regarding this experimen t are provided in Table S1 of th e Addition al file 4.
Table S2 of th e Additional file 4 shows the m ost seven pair
com bin ations foun d in the experim ent. Each of th e seven
gen e pairs generates four rules, which can be sim plified
into th ree equivalent rules. The rules can be used to correctly classify 148 of 149 sam ples in the test set, with only
one error (one m esotheliom a was m isclassified as ADCA).

The detailed rules formed by the seven pairs of genes are
presented in the Additional file 3.
Prostate Cancer dataset
Because of differences in m icroarray intensity between the
training set and the test set, we first norm alized the
attribute values for both sets. Every attribute value was
norm alized to a num ber between -1 and 1. In this dataset,
if the depended degree standard is employed for gen e
selection, it is som ewhat difficult to find authentically discrim inative genes, as no gene has a 100% depended
degree, and the highest depended degree in the training
set is 36%. Therefore, we utilized the α depended degree
as the criterion for gene selection. For α ≥ 0.9, no comm on
gene was detected am ong all of the 102 leave-one-out
training sets; when α = 0.85, gene #10493 was found;
when α = 0.80, nine genes were found. Of these nine
genes, we excluded gene #5261 with three distinct values,
and calculated the LOOCV accuracy of the other eight

Page 8 of 23
(page number not for citation purposes)

BMC Medical Genomics 2009, 2:64

http://www.biomedcentral.com/1755-8794/2/64

T able 5: T went y-five gene pair s wit h 100% LOO CV accur acy in t he Lung Cancer dat aset

1st - 2nd Pr obe ID

Classificat ion r esult s in t he t est set
# Cor r ect ly classified sam ples

A ccur acy (%)

33754_at - 36562_at

144 (13/131)

96.64 (86.67/97.76)

33754_at - 40496_at

143 (11/132)

95.97 (73.33/98.51)

34105_f_at - 40496_at

141(9/132)

94.64 (60/98.51)

34105_f_at - 36562_at

140 (10/130)

93.96 (66.67/97.01)

37004_at - 40496_at

140 (11/129)

93.96 (73.33/96.27)

36562_at - 37004_at

139 (13/126)

93.29 (86.67/94.03)

38827_at - 40445_at

138 (15/123)

92.62 (100/91.79)

1882_g_at - 36562_at

136 (11/125)

91.28 (73.33/93.28)

1882_g_at - 40496_at

136 (10/126)

91.28 (66.67/94.03)

33907_at - 36562_at

134 (10/124)

89.93 (66.67/92.54)

36562_at - 40496_at

134 (9/125)

89.93 (60/93.28)

1882_g_at - 33907_at

133 (11/122)

89.26 (73.33/91.04)

1882_g_at - 37004_at

132 (13/119)

88.59 (86.67/88.81)

35947_at - 36269_at

132 (12/120)

88.59 (80/89.55)

33907_at - 34105_f_at

131(9/122)

87.92 (60/91.04)

36269_at - 40445_at

131(14/117)

87.92 (93.33/87.31)

35947_at - 40445_at

130 (14/116)

87.25 (93.33/86.57)

38074_at - 38827_at

129 (14/115)

86.58 (93.33/85.82)

33907_at - 40496_at

127(8/119)

85.23 (53.33/88.81)

36269_at - 38074_at

125 (13/112)

83.89 (86.67/83.58)

38074_at - 40445_at

122 (13/109)

81.88 (86.67/81.34)

1117_at - 38827_at

116 (15/101)

77.85 (100/75.37)

1117_at - 36269_at

113 (13/100)

75.84 (86.67/74.63)

1117_at - 35947_at

109 (12/97)

73.15 (80/72.39)

1117_at - 38074_at

106 (14/92)

71.14 (93.33/68.66)
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genes. Relatively h igh LOOCV outcom es were obtained.
Applying the decision rules induced by each of the eigh t
gen es in the trainin g set, we classified the test set and
ach ieved satisfactory classification results (see Table 6).
Th e classification rules gen erated by the eight genes are
presented in the Additional file 5.
As for gene pairs, wh en α = 0.75 an d the th reshold of the
positive region sizes caused by sin gle gen es was 13, 16
gene pairs were shared by all 102 of th e leave-on e-out
trainin g sets. The LOOCV accuracy of th e 16 gene pairs
was between 81% an d 86%, yet th ere were three pairs of
genes with relatively good classification perform ance in
the test set (Table 7). The classification rules gen erated by
the th ree pairs are presented in the Addition al file 5.
We also analyzed th e train ing set based on the depen ded
degree. We ran ked all of th e gen es in th e discretized training set by their depended degrees. The top two genes,
37639_at and 41755_at, had the h ighest depen ded degree
of 36%. When we exam ined the rules form ed by gene
37639_at, we foun d the followin g: if g(37639_at) > 0.491443, th en Tum or (100% confiden ce); if
g(37639_at) ≤ -0.694377, then Norm al (95% confidence). Both rules were highly reliable. Using th e two
rules, we correctly classified 33 of the 34 test sam ples. This
result indicates that gene 37639_at possessed h igh classdiscrimin ation power. Th e rules arising from this gene
indicate that it is relatively high ly expressed in tumor sam ples. Gene 41755_at produced th e followin g two rules: if
g(41755_at) > 0.261438, then Tum or (100% confiden ce);
if g(41755_at) ≤ -0.477124, th en Normal (100% confidence). Using th ese two rules, 14 of th e 34 test sam ples
were classified correctly, whereas all 9 sam ples labeled

"Norm al" were classified correctly. The rules implied that
gene 41755_at is expressed at a low level in norm al sam ples. Apart from 37639_at and 41755_at, gene
38087_s_at produced the following rule: if g(38087_s_at)
> -0.281725, then Norm al (100% confidence). We correctly classified six of nine norm al sam ples using the rule,
indicating that this gene is com paratively highly expressed
in norm al sam ples. Inform ation on the top 20 genes
ranked based on depended degree is provided in the Additional file 6.
Breast Cancer dataset
In the dataset, when α ≥ 0.8, no shared gene was detected
in all of the 78 leave-one-out training sets; when α = 0.75,
four genes were found; when α = 0.70, 46 genes were
found. Most of these 46 genes had LOO CV accuracy ranging from 70% to 80%, while a few had LOOCV accuracy
slightly less than 70%. Using each of the 46 genes to classify the test set, we found eight genes by which no less
than 13 of the 19 test sam ples were classified correctly.
Inform ation on the eight genes is listed in Table 8. The
classification rules generated by each of the eight genes are
available in the Additional file 7. In the dataset, we did
not find any gene pairs with satisfactory classification perform ance. The best classification accuracy obtained by
gene pairs was 12 test sam ples classified correctly; accuracy was 63.16%.
Leukemia dataset 2
This dataset contains three classes, being a m ulti-class
classification problem . When α ≥ 0.95, no shared gene
was detected in the 57 leave-one-out training sets; when α
= 0.9 and 0.85, a single gene was found; when α = 0.80,
five genes were found; when α = 0.75, eight genes were

T able 6: Eight genes wit h high classificat ion accur acy in t he Pr ost at e Cancer dat aset

Pr obe ID

Classificat ion r esult s in LOOCV

Classificat ion r esult s in t he t est set

α

# Cor r ect ly classified sam ples

A ccur acy (%)

# Cor r ect ly classified sam ples

A ccur acy (%)

32598_at

92 (50/42)

90.20 (96.15/84.00)

23 (17/6)

67.65 (68.00/66.67)

0.85

36491_at

84 (41/43)

82.35 (78.85/86.00)

30 (23/7)

88.24 (92.00/77.78)

0.80

40856_at

85 (46/39)

83.33 (88.46/78.00)

23 (15/8)

67.65 (60.00/88.89)

0.80

32243_g_at

84 (41/43)

82.35 (78.85/86.00)

31 (22/9)

91.18 (88.00/100)

0.80

36601_at

85 (46/39)

83.33 (88.46/78.00)

17 (8/9)

50.00 (32.00/100)

0.80

38044_at

81 (41/40)

79.41 (78.85/80.00)

29 (21/8)

85.29 (84.00/88.89)

0.80

41288_at

88 (41/47)

86.27 (78.85/94.00)

31 (22/9)

91.18 (88.00/100)

0.80

1767_s_at

83 (40/43)

81.37 (76.92/86.00)

24 (22/2)

70.59 (88.00/22.22)

0.80
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T able 7: T hr ee gene pair s wit h good classificat ion accur acy in t he Pr ost at e Cancer dat aset

1st - 2nd Pr obe ID

Classificat ion r esult s in LOOCV
# Cor r ect ly classified
sam ples

Classificat ion r esult s in t he t est set

A ccur acy (%)

# Cor r ect ly classified
sam ples

A ccur acy (%)

α

35178_at - 35277_at

83 (33/50)

81.37 (63.46/100)

26 (20/6)

76.47 (80.00/66.67)

0.7
5

35178_at - 38087_s_at

83 (33/50)

81.37 (63.46/100)

27 (21/6)

79.41 (84.00/66.67)

0.7
5

39331_at - 33121_g_at

86 (38/48)

84.31 (73.08/96.00)

27 (18/9)

79.41 (72.00/100)

0.7
5

foun d; when α = 0.70, 21 genes were identified. Almost
every one of these 21 genes had a high LOOCV accuracy
an d good classification perform ance in th e test set. Their
classification in form ation is listed in Table 9. Gen e
36239_at had the best LOOCV accuracy an d classification
accuracy in the test set. Th e classification rules induced by
this gene were as follows: if g(36239_at) > 1796.5, then
ALL; if g(36239_at) > 214 and g(36239_at) ≤ 1796.5, th en
MLL; if g(36239_at) ≤ 214, th en AML; with 95.24%,
93.33%, an d 90.48% confidence, respectively. Using
these three rules, we correctly classified 14 of the 15 test

sam ples; accuracy reached 93.33%. The other genes produced sim ilar classification rules. The classification rules
generated by every gene can be found in the Additional
file 8. We did not exam ine gene pairs for the classification,
as the rules induced by gene pairs tended to be com plex.
Comparison and analysis of results
Leukemia dataset 1
Other researchers have explored the problem concerned
with the classification of the dataset using rule-based
machine-learning m ethods. In [7], the authors proposed

T able 8: Eight genes wit h high classificat ion accur acy in t he Br east Cancer dat aset

GenBank accession
num ber

Classificat ion r esult s in LOOCV

Classificat ion r esult s in t he t est set

α

# Cor r ect ly classified
sam ples

A ccur acy (%)

# Cor r ect ly classified
sam ples

A ccur acy (%)

NM_012261

57 (21/36)

73.08 (61.76/81.82)

16 (10/6)

84.21 (83.33/85.71)

0.7
0

AW237580

58 (18/40)

74.36 (52.94/90.91)

13 (8/5)

68.42 (66.67/71.43)

0.7
0

U45975

58 (22/36)

74.36 (64.71/81.82)

13 (9/4)

68.42 (75.00/57.14)

0.7
0

AI742029

55 (17/38)

70.51 (50.00/86.36)

13 (11/2)

68.42 (91.67/28.57)

0.7
0

NM_001689

57 (22/35)

73.08 (64.71/79.55)

15 (9/6)

78.95 (75.00/85.71)

0.7
0

TSPYL5

58 (24/34)

74.36 (70.59/77.27)

16 (10/6)

84.21 (83.33/85.71)

0.7
0

NM_000271

57 (20/37)

73.08 (58.82/84.09)

13 (9/4)

68.42 (75.00/57.14)

0.7
0

AL049689

55 (22/33)

70.51 (64.71/75.00)

13 (10/3)

68.42 (83.33/42.86)

0.7
0
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T able 9: T went y-one genes wit h high classificat ion accur acy in t he Leukem ia dat aset 2

Pr obe ID

Classificat ion r esult s in LOO CV

Classificat ion r esult s in t he t est set

α

# Cor r ect ly classified sam ples

A ccur acy (%)

# Cor r ect ly classified sam ples

A ccur acy (%)

36239_at

51 (20/12/19)

89.47 (100/70.59/95)

14 (4/2/8)

93.33 (100/66.67/100)

0.90

39318_at

47 (17/11/19)

82.46 (85/64.71/95)

13 (2/3/8)

86.67 (50/100/100)

0.80

40191_s_at

48 (17/13/18)

84.21 (85/76.47/90)

12 (2/2/8)

80 (50/66.67/100)

0.80

840_at

47 (19/10/18)

82.46 (95/58.82/90)

11 (3/1/7)

73.33 (75/33.33/87.50)

0.80

266_s_at

46 (19/11/16)

80.70 (95/64.71/80)

13 (4/1/8)

86.67 (100/33.33/100)

0.80

37933_at

45 (20/7/18)

78.95 (100/41.18/90)

8 (2/0/6)

53.33 (50/0/75)

0.75

38989_at

43 (19/6/18)

75.44 (95/35.29/90)

12 (3/1/8)

80 (75/33.33/100)

0.75

33833_at

44 (16/10/18)

77.19 (80/58.82/90)

10 (2/0/8)

66.67 (50/0/100)

0.75

32874_at

43 (14/11/18)

75.44 (70/64.71/90)

10 (2/1/7)

66.67 (50/33.33/87.5)

0.7

37487_at

41 (14/7/20)

71.93 (70/41.18/100)

11 (3/0/8)

73.33 (75/0/100)

0.7

31886_at

42 (16/8/18)

73.68 (80/47.06/90)

13 (3/2/8)

86.67 (75/66.67/100)

0.7

35164_at

48 (19/15/14)

84.21 (95/88.24/70)

13 (4/2/7)

86.67 (100/66.67/87.5)

0.7

36905_at

46 (14/12/20)

80.70 (70/70.59/100)

9 (0/1/8)

60 (0/33.33/100)

0.7

37539_at

50 (16/16/18)

87.72 (80/94.12/90)

10 (3/3/4)

66.67 (75/100/50)

0.7

37910_at

45 (18/9/18)

78.95 (90/52.94/90)

9 (1/1/7)

60 (25/33.33/87.5)

0.7

32847_at

44 (18/12/14)

77.19 (90/70.59/70)

11 (4/2/5)

73.33 (100/66.67/62.5)

0.7

35260_at

42 (20/8/14)

73.68 (100/47.06/70)

9 (2/1/6)

60 (50/33.33/75)

0.7

41790_at

47 (19/11/17)

82.46 (95/64.71/85)

13 (3/2/8)

86.67 (75/66.67/100)

0.7

32579_at

48 (15/13/20)

84.21 (75/76.47/100)

11 (2/1/8)

73.33 (50/33.33/100)

0.7

1373_at

47 (16/12/19)

82.46 (80/70.59/95)

10 (1/1/8)

66.67 (25/33.33/100)

0.7

1325_at

47 (19/14/14)

82.46 (95/82.35/70)

10 (3/3/4)

66.67 (75/100/50)

0.7

first usin g feature ranking (t-test) and then rough sets
attribute reduction for gen e selection. Th ey ultimately
identified one gene, wh ich classified 31 sam ples correctly
in the test set. This gene was the gene identified in the
present study: gene #4847. However, our m eth od identified not on ly this gene, but also oth er inform ative genes,
includin g one gene pair with 100% classification accuracy. In [8], the authors also used rough sets for gene selection. They chose genes with m aximum relevan ce with

respect to the class variable and the m axim um positive
interaction between different genes. We also selected
genes with maxim um relevance with respect to the class
variable (i.e., the depended degree of a single gene), while
we chose gene pairs with maximum relevance with respect
to the class variable rather than maxim um positive interaction between the genes, since the m axim um positive
interaction between two genes m ay counteract the
depended degree of a single gene. Because this previous
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study assessed classification perform an ce using LOOCV
on a total of 72 sam ples in stead of separatin g th em in to
training an d test sets, it is impractical to com pare th eir
results with those of th e presen t study. Likewise, in [9] the
auth ors took in to accoun t all attributes dependin g upon
the degree of dependency. Th ey selected the top λ
attributes ( λ = 2, 4, 6, 8, 10, 12, 14, 15) by the degree of
dependen cy, and foun d all possible com bination s of
these λ attributes as a subset. The auth ors calculated the
depended degrees of every subset an d ch ose th ose with
100% depen ded degrees. Fin ally, th ey evaluated the classification perform ance of the selected subsets using kNNs. In essence, their method was to find th e reducts with
lim ited sizes an d to use them for classification . As we
m ention ed above, fin din g all of the reducts is com putationally intensive, even for a sm all attribute n um ber.
Moreover, on e reduct does not in dicate h igh classification
performan ce. Another difference between our m eth od
an d that of [9] is th at our classifier is based on rules,
wh ereas theirs is not. Although th ey gain a classification
score of 97% with gene subsets of size two, th ey did n ot
find any gene pair with a classification score of 100%, and
they did not identify any im portant gen es. In [10], a
m eth od of com bining rough sets with GAs was proposed
to classify m icroarray gen e expression pattern s. A correct
classification of 90.3% was obtained with a nine-gene
classifier in th e dataset.
In [6], th e auth ors used the EPs approach to m ark one
im portant gene, Zyxin , wh ich is our gen e #4847. Using
the two rules induced by the gene, the authors accurately
classified 31 sam ples, the same result as ours. However,
they did not identify an y gene pair with h igher classification performance, as we did. In [11], th e auth ors used
decision trees (Sin gle C4.5, Baggin g C4.5, AdaBoost C4.5)
to perform classification tasks on seven publicly available
can cerous microarray datasets, in cludin g the ALL-AML
leukem ia data. Th ey first em ployed Fayyad and Irani's
[21] discretization m ethod to filter out n oise. The rem ain ing 1038 gen es were used in th e actual learnin g process.
Th eir highest accuracy was 91.2% (31 sam ples classified
correctly). Sin ce the auth ors did not report the size of the
pruned decision trees, we h ave no kn owledge of how
m an y genes th ey used to reach the highest accuracy. In
[13], 91.2% classification accuracy was achieved by usin g
the rule classifiers con tainin g gene subsets with sizes ran ging from 10 to 40. In [14], the auth ors utilized a sin gle
pair of gen es to correctly classify 31 test set samples.
Besides, a n um ber of differen t non-rule-based m eth ods
h ave been proposed for gen e selection and cancer classification in th e dataset. Golub et al. [2] were the first to classify ALL-AML by gen e expression data. The authors
con structed th e predictor using 50 inform ative genes,
trained by weigh ted votin g on the train ing set. The predic-

http://www.biomedcentral.com/1755-8794/2/64

tion rates included 36 sam ples classified correctly, with
two sam ples labeled "uncertain" in LOOCV, as well as 29
of the 34 samples in the test set classified correctly, with
no predictions made for the remaining five samples. In
[23], the authors applied probabilistic neural networks
(PNNs) to the class prediction of ALL-AML, and achieved
100% prediction accuracy in the test set using the 50-gene
predictors derived from cross-validation tests of the training set by m eans of the signal-to-noise statistic feature
selection m ethod. In [24], the authors used a correlationbased feature (CBF) selector in conjunction with
machine-learning algorithms such as decision trees
(JP48), NB, and SVMs to analyze cancer m icroarray data.
They reported one noteworthy gene, Zyxin, which classified 31 sam ples correctly. In [25], the authors proposed a
maxim al margin linear program ming (MAMA) method
for the classification of tum or sam ples based on microarray data. This procedure detected groups of genes and constructed models that strongly correlated with particular
tum or types. They achieved 100% prediction accuracy on
the test set using gene subsets ranging in size from 132 to
549. In [26], the authors proposed dim ension reduction
using partial least squares (PLS) and classification using
logistic discrim ination (LD) and quadratic discrim inant
analysis (QDA). By using gene subsets with sizes between
50 and 1500, the authors obtained correct classification of
the test samples ranging from 28 to 33. In [27], th e
authors used SVMs trained and gene subsets selected in
the training set to classify samples in the test set, resultng
in the correct classification of between 30 and 32 of the 34
sam ples. Other SVM-based m ethods report zero test error
with gene subsets ranging in size from 8 to 30 [28-30].
Table 10 com pares our m ethods with those em ployed in
previous studies. The table reveals that our classification
results are superior to alm ost all of those obtained in previous studies.
In this dataset, we identified 11 genes that show good classification perform ance alone or in com bination with
another gene. These genes are Zyxin, MGST1, TCRA,
APLP2, CCND3, HKR-T1, KIAA0159, TOP2B, MB-1,
ARHG, and IOTA. Am ong these, Zyxin, CCND3, HKR-T1,
TOP2B, MB-1, and IO TA also belong to the list of th e 50
inform ative genes identified by Golub et al. [2]; Zyxin is
highly expressed in AML, and the rest are highly expressed
in ALL. Our rules relevant to these genes revealed that
Zyxin, MGST1, APLP2, and ARHG are upregulated in
AML, while TCRA, CCND3, HKR-T1, KIAA0159, TOP2B,
MB-1, and IOTA are upregulated in ALL. These results
demonstrate that our rules are reasonable.
Our m ethod identified an outstanding gene, Zyxin, by
which we classified the test set with 91.2% accuracy. The
gene is also referred to by other researchers
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T able 10: Com par ison of best classificat ion accur acy for t he Leukem ia dat aset 1

Met hods (feat ur e select ion + classificat ion) a

#Select ed genes

#Cor r ect ly classified sam ples (accur acy)

Rule-based classifier

depended degree + decision rules [this work]

1

31 (91.18%)

yes

2

34 (100%)

t-test, attribute reduction + decision rules [7]

1

31 (91.18%)

yes

attribute reduction + k-NNs [9]

2

33 (97.06%)

no

rough sets, GAs + k-NNs [10]

9

31 (91.18%)

no

EPs [6]

1

31 (91.18%)

yes

discretization + decision trees [11] b

unknownc

31 (91.18%)

yes

CBF + decision trees [24]

1

31 (91.18%)

yes

TSP [14]

2

31 (91.18%)

yes

RCBT [13]

10-40

31 (91.18%)

yes

neighborhood analysis + weighted voting [2]

50

29 (85.29%)

no

signal to noise ratios + PNNs [23]

50

34 (100%)

no

MAMA [25]

132-549

34 (100%)

no

PLS + LD or QDA [26]

50-1500

28-33 (82.4%-97%)

no

prediction strength + SVMs [27]

25-1000

30-32 (88.2%-94.1%)

no

SVMs [28-30]

8-30

34 (100%)

no

aThe text

before "+" states the feature selection method, while that after it states the classification method. The absence of "+" means that the same
method was used for both feature selection and classification.
bThe decision trees are also involved in feature selection.
c"unknown" means that no related data are provided in the article.
These explanations apply to the other tables.

[2,6,7,23,24,26,27,31-36]. Our results an d th ose of other
related studies suggest th at the expression level of Zyxin
plays an im portan t role in distinguishing ALL from AML.
Zyxin is a focal-adhesion-associated ph osphoprotein with
one dom ain in volved in th e con trol of actin assem bly and
three protein-protein adapter domains im plicated in the
regulation of cell growth an d differentiation. Zyxin m ay
function as a m essen ger in the sign al transduction pathway that mediates adhesion-stim ulated chan ges in gene
expression . As n oted in [36], cell spreading, proliferation,
an d survival are modulated by focal adhesion s lin king
extracellular m atrix protein s, integrin s, an d th e cytoskeleton. By supporting th e involvem ent of th e m icrofilamen t
n etwork in tum or cell beh avior, several actin -bin din g proteins, includin g Zyxin, a potential regulator of actin
polym erization , may play a role in oncogen esis. The gene

encoding Zyxin m aps at 7q32, a chromosom al region
affected in a variety of hum an cancers. 7q m onosom y or
partial deletion of this chrom osom e arm is frequently
found in m yelodysplastic syndrom e, acute myeloid, juvenile m yelom onocytic, and acute lymphocytic leukem ias,
as well as in breast carcinom a [37,38]. Valdes et al.
revealed that the actin cytoskeleton-associated protein
Zyxin acts as a tum or suppressor in Ewing tumor cells
[32]. Yagi et al. also identified Zyxin as one of 35 genes
associated with pediatric AML prognosis [31]. Taken
together, these lines of evidence suggest that Zyxin plays
an im portant role in leukemia pathogenesis.
The aforementioned gene pair, MGST1 vs. TCRA, is capable of classifying the test set with zero error. Their biological m eanings are noteworthy. MGST1 is also one of the
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three core gen es screen ed by Ban erjee et al. [10]. In [24],
the gene lies in th e first 10 gen es selected by th e m eth ods
of χ2 , In foGain, ReliefF, an d symm etrical uncertainty. In
[23], MGST1 belon ged to th e set of top 50 gen es selected
by signal-to-noise m etric (10-fold cross-validation tests).
In our 13 gen e pairs with th e high est classification performance, MGST1 occurred five tim es. These facts demonstrate th at MGST1 is significant in the classification of
ALL-AML. Although it has n ot been identified by other
algorith m s, the gene TCRA is clearly im portan t in the
path ogenesis of leukem ia [39-41].

method is higher than that of other rule-based classification algorithms, including PCLs and the decision trees
mentioned in [50]. The highest classification accuracies
on the dataset, using the three different decision trees
reported in [11], were about 93%. In [13], the best result
was 98% classification accuracy. In the initial research
article on the dataset [15], the authors reported 99% classification accuracy using six genes. Table 11 com pares our
results with those of other studies, revealing that our outcom es matched or outperform ed those obtained using
other methods.

APLP2 was one of the first 10 gen es selected by Wang et al.
[24], and was identified by Huang et al. [23]. It was also
identified by Yagi et al. [31] as on e of 35 gen es associated
with pediatric AML prognosis. CCND3 is also listed as one
of the 50 gen es selected by Huang et al. [23]. KIAA0159 is
an essential com pon en t of th e human con densin com plex
required for m itotic ch rom osom e con densation. In a brief
examin ation of related literature, we found that the gene
h as not been iden tified by other algorith m s. However,
past studies h ave in dicated th at n onran dom ch rom osomal tran slocation s are characteristic of most h um an
h ematopoietic m align an cies [42]. Because KIAA0159 is
correlated with the structural m ain tenan ce of ch rom osomes, it m ay be associated with the path ogen esis of
leukem ia. TOP2B encodes th e protein that is th e principal
target of th e an tileukemic drug etoposide [2,43,44]. MB-1
en codes th e Ig-alph a protein of the B-cell an tigen com pon ent. Its dysregulation has been reported to be closely
lin ked to leukem ia and lymph om a [45-48]. ARHG is a
m em ber of th e RAS superfam ily of genes, which encode
GTP-bin din g protein s that act in th e path way of signal
transduction and play a key role in th e regulation of cellular function s [49].

We now explain in more detail the results presented in
[15]. The article proposed to use the expression levels of a
small num ber of genes for the diagnosis of MPM and lung
cancer. The authors screened out eight genes with m arked
differences in average expression levels between the tum or
types in the training set. They then calculated 15 expression ratios for each sam ple by dividing the expression
value of each of the five genes expressed at relatively
higher levels in MPM by the expression value of each of
the three genes expressed at relatively higher levels in
ADCA. Next, they em ployed these ratios for the test set.
Sam ples with ratio values > 1 were classified as MPM, and
those with ratio values < 1 were classified as ADCA. They
achieved classification accuracies ranging from 91% to
98%. In essence, they also utilized gene pairs for classification. Yet, when following the same protocol for training
and testing, our results are superior to theirs, in that they
used three ratios (i.e., six genes) to reach 148 of 149 correctly classified samples, while we obtained the sam e
result using each of the seven gene pairs directly selected
from the training set without the LOOCV procedure. Of
note, six of the eight genes selected in this earlier study
were also identified in the present study. The six genes are
PTGIS, CD200, TACSTD1, TTF1, ANXA8, and CALB2, the
first three of which have a 100% depended degree.

In general, th e genes iden tified in the presen t study are all
directly or in directly relevant to h em atopoietic or cancerous pathogen esis. Th erefore, th ey are likely to play key
roles in the pathogen esis of ALL or AML. It is possible th at
they h ave high perform an ce in distin guishin g ALL from
AML.
Lung Cancer dataset
In [9], th e auth ors used rough sets to handle th e sam e
dataset as th at considered in the present study. Their best
result was 98% classification accuracy with genes of size
two. As they em ployed a n on-rule-based classifier, k-NN,
n o rule was given to explain th e result. In [50], in terms of
classification perform an ce, the authors compared prediction by collective likelihoods (PCLs), based on th e concept of EPs, with other classification algorithm s, in cluding
decision trees, SVMs, and k-NNs. Regardin g th e Lung Can cer dataset, th ey obtained classification results con taining
between 1 an d 27 errors. Th e classification accuracy of our

The genes selected by our m ethod are associated primarily
with the pathogenesis of MPM or ADCA or som e other
tum or. According to our rules, JUP, CD24, PRKCD,
MAPK13,
TACSTD2,
DKFZP564O0823
protein,
TACSTD1, CEACAM1, XBP1, TTF1, SFTPB, AGR2, ELF3,
EVI1, and CDA are highly expressed in ADCA, while EGF,
SPTAN1, FLNC, PTGIS, FBXL7, CD200, AP2 M1, ANXA8,
HAS1, CALB2, GFPT2, KIAA0427, C1S, EIF4G3, TGM1,
Adamts3, hypothetical protein dJ465N24.2.1, and AP3S1
are highly expressed in m esotheliom a. CALB2 encodes
calretinin, which is a component of several im m unohistochem ical panels currently used in the diagnosis of MPM
and lung cancer [15]. HAS1 is a mem ber of gene fam ily
HA, which has been correlated with tumor m etastasis. In
[51], HAS1 was identified as a prognostic gene for mesothelioma. In [52], HAS1 belongs to the list of the genes
with elevated expression levels in C1 MPM tumors. We
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T able 11: Com par ison of best classificat ion accur acy for t he Lung Cancer dat aset

Met hods (feat ur e select ion + classificat ion)

#Select ed genes

#Cor r ect ly classified sam ples (accur acy)

Rule-based classifier

depended degree + decision rules [this work]

1

145 (97.34%)

yes

2

144 (96.64%)

attribute reduction + k-NNs [9]

2

146 (97.99%)

no

PCLs [50]

unknown

146 (97.99%)

yes

C4.5 [50]

1

122 (81.88%)

yes

Bagging [50]

unknown

131 (87.92%)

yes

Boosting [50]

unknown

122 (81.88%)

yes

SVMs [50]

unknown

148 (99.33%)

no

k-NNs [50]

unknown

148 (99.33%)

no

discretization + decision trees [11]

unknown

139 (93.29%)

yes

RCBT [13]

10-40

146 (97.99%)

yes

gene expression ratios [15]

6

148 (99.33%)

no

h ave one rule arising from HAS1: if g(HAS1) > 7.3, then
MPM. Th is rule is con sisten t with th e results of [51,52].
ANXA8, PTGIS, and CLAB2 are also m arked as more
h igh ly expressed gen es in C1 MPM tum ors [52]. Th ese
observation s are supported by the following rules of the
present study: if g(ANXA8) > 130.8, th en MPM; if
g(CALB2) > 490.5, then MPM; if g(PTGIS) > 193.25, th en
MPM. Oth er genes that we chose (e.g., CD24, TACSTD1,
TACSTD2, CEACAM1, and PRKCD) are correlated with
lung carcin om a or oth er tum ors. TTF1 is a tran scription
factor th at regulates the expression of m ultiple genes
involved in lung developm ent. It is preferentially
expressed in ADCAs of the lung an d has been investigated
as a potential prognostic param eter in patients with lung
can cer [53-56].
Prostate Cancer dataset
Regardin g the Prostate Can cer dataset, a previous study
reported a 95% prediction rate usin g a gene pair [14]. The
best classification results on th e dataset, based on three
differen t decision tree approach es (Single C4.5, Bagging
C4.5, an d AdaBoost C4.5), are 67.65%, 73.53%, and
67.65%, respectively [11]. In [13], a 97% classification
result was reported, but th e em ployed gen e numbers were
n ot provided. In [18], the authors built predictors usin g a
k-NN algorith m, an d achieved 77% and 86% prediction
accuracy on the test set with 4 and 16 genes, respectively.

Table 12 summ arizes the best results of classification on
the dataset.
In the Prostate Cancer dataset, we identified 13 genes
using the LOOCV approach. Seven of the eight single
genes had relatively good classification perform ance, of
which five genes had established names: NRP2,
TMSB15A, PEDF, FAM107A and TGFB3. Our rules im ply
that TMSB15A, also nam ed thymosin beta15, is highly
expressed, while NRP2, PEDF, FAM107A and TGFB3 are
expressed at low levels in tumor tissue. As revealed in [57],
thymosin beta15 levels are elevated in hum an prostate
cancer and correlate positively with the Gleason tumor
grade. Thym osin beta 15 may represent a potential n ew
biochemical m arker for the progression of hum an prostate cancer; our rules strengthen this perspective. Previous
investigations have revealed that PEDF expression is negatively correlated with tum or m alignancy [58-62]; our
rules support this viewpoint. FAM107A has been consistently reported to be downregulated in human cancer
[63,64]; that conforms to our rules. In the gene pairs, our
rules indicate that KIAA0762 is downregulated, while
TUBB and RGS10 are upregulated in tum or tissue; however, there exists insufficient evidence to directly link the
three genes with prostate cancer.
The three genes that we identified directly from th e training set are hepsin (37639_at), KIAA0977 (41755_at), and
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T able 12: Com par ison of best classificat ion accur acy for t he Pr ost at e Cancer dat aset

Met hods (feat ur e select ion + classificat ion)

#Select ed genes

#Cor r ect ly classified sam ples (accur acy)

Rule-based classifier

depended degree + decision rules [this work]

1

31 (91.18%)

yes

2

27 (79.41%)

TSP [14]

2

32 (94.12%)

yes

PCLs [50]

unknown

33 (97.06%)

yes

discretization + Single C4.5 [11]

unknown

23 (67.65%)

yes

discretization + Bagging C4.5 [11]

unknown

25 (73.53%)

yes

discretization + AdaBoost C4.5 [11]

unknown

23 (67.65%)

yes

RCBT [13]

unknown

33 (97.06%)

yes

SVMs [13]

unknown

27 (79.41%)

no

signal to noise ratios + k-NNs [18] d

4

26 (77.2%)

no

16

29 (85.7%)

no

dIn

[18], as both raw and normalized datasets were used, two groups of prediction results were obtained. Here, we chose their results from the
normalized dataset. Another small difference is that we obtained the dataset from the Kent Ridge Bio-medical Data Set Repository, where the
prostate test set includes 25 tumor and 9 normal samples instead of the 27 tumor and 8 normal samples studied in [69]. To facilitate comparison,
the correctly classified sample numbers were calculated according to the total of 34 samples.

S100A4 (38087_s_at). Hepsin performs reason ably well
in differentiating two classes of sam ples, and the latter two
genes are good indicators of norm al sam ples. Hepsin is
the h uman h epatoma m RNA for serin e protease. Numerous studies have revealed th at it is closely lin ked to prostate cancer. Hepsin is widely reported to be h ighly overexpressed in more th an 90% of h um an prostate tumors,
m aking it a significant m arker and a target for prostate
can cer [65-72]. In [18], h epsin was identified as th e first
over-expressed gen e in tum or sam ples an d was selected as
one of 16 genes used for creating a prediction m odel. All
of these outcomes strongly support our rules involved in
h epsin. Another gene, KIAA0977, h as also been listed as a
h igh ly expressed gen e in tumor sam ples [18]. The third
gen e, S100A4, was associated with can cer path ogenesis,
chrom osom al rearran gements and altered expression of
wh ich have been im plicated in tum or m etastasis [73-75].
In [18], S100A4 was iden tified as one of th e h igh ly
expressed genes in norm al samples an d ch osen as one
m em ber of a 16-gen e m odel of prediction. In addition ,
[76] noted that S100A4 protein was not expressed in
benign or m align ant prostatic epith elium or in LNCaP
an d Du145 cells. Our rules related to this gen e support
these previous fin din gs. A surprising result is th at many
observation s h ave revealed th at S100A4 is over-expressed
in most other tumors [77-82], yet in [76] th e authors suggested that the m ech an ism of ch anges in th e expression

level of S100A4 m ay involve m ethylation of the S100A4
gene.
Breast Cancer dataset
In the Breast Cancer dataset, our best LOOCV accuracy
was 74.34%, and the highest classification accuracy in the
test set was 84.21% with one gene. In [19], the authors
reported 83.33% LOOCV accuracy and 89.47% accuracy
in the test set using the 70-gene predictor. These prediction results are moderately superior to those attained in
the present study, although using a m uch larger num ber
of genes. Likewise, Tan et al. [11] obtained a slightly better
classification outcom e than that of the present study,
although they used far m ore genes. Table 13 lists som e of
the best classification results for this dataset, as obtained
using a variety of m ethods.

In this dataset, we identified eight genes with relatively
high individual classification perform ance. Our rules
indicated that the overexpression of ATP5G3, TSPYL5, or
NPC1 m eans an unfavorable prognosis, while the overexpression of HS1119D91, Contig38726_RC, PIB5PA,
Contig51517_RC, or LOC63923 im plies a favorable prognosis. TSPYL5 had the best classification accuracy in our
model; it was also chosen as one of 70 prognostic marker
genes and ranked first according to the correlation coefficient with the two prognostic groups [19]. It follows that
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T able 13: Com par ison of best classificat ion accur acy for t he Br east Cancer dat aset

Met hods (feat ur e select ion + classificat ion)

#Select ed genes

#Cor r ect ly classified sam ples (accur acy)

Rule-based classifier

α depended degree + decision rules [this work]

1

16 (84.21%)

yes

TSP [14]

2

79.38%e

yes

RBF [50]

67

79.38%e

yes

discretization + decision trees [11]

unknown

17 (89.47%)

yes

correlation coefficient [19]

70

17 (89.47%)

no

eLOOCV result

in the total of 97 samples.

our gen e selection approach is reason able. In [83], the
auth ors proposed a prognostic predictor of breast can cer
with m ultiple fuzzy n eural models usin g th e same dataset.
Surprisin gly, although these m ethods are distinct from
those of the presen t study, th ere is an overlap of 3 genes
between th e 10 h ighest-ranked gen es they ch ose for prediction and our 8-gen e group.
Leukemia dataset 2
Although th is dataset is in volved in a m ulti-class classification problem , we still achieved relatively good classification outcom es. Our best prediction rate was 93.33% in
the test set an d 89.47% LOOCV accuracy in the training
set, each by on e gene, com pared with a 90% prediction
rate in th e test set by 100 genes an d 95% LOOCV accuracy
in th e trainin g set by 40 genes, as reported by Arm strong
et al. [84]. In addition , Wang et al. reported 100% LOOCV
accuracy in all 72 sam ples usin g 26 genes; h owever, their
m eth ods were n ot verified by an in depen dent test set.
Th ese outcomes are presented in Table 14.

Regardin g the Leukem ia dataset 2, each chosen gene
induced 3 rules with th e following form: if g(x) > a, then
class 1; if b < g(x) ≤ a, then class 2; if g(x) ≤ b, then class 3.
Th at is, if the expression level of gen e x in a sam ple is rel-

atively high, then the sam ple is assigned to class 1; if the
expression level is m oderate, then the sam ple is assigned
to class 2; if the expression level is relatively low, then the
sam ple is assigned to class 3. According to the standard,
we predicted the class of every sam ple based on its expression value on the chosen genes. In total, we identified 21
genes with comparatively strong prediction power. O f
these genes, 36239_at (OBF-1) and 31886_at (human
placental cDNA coding for 5' nucleotidase) are also contained in the best 26-gene prediction m odel proposed in
[85]. It is noteworthy that OBF-1 was ranked as the top of
these 26 genes, and it yields the best prediction outcom e
in our m ethods. This finding dem onstrates that our decision-rule-based classification approach is superior to the
clustering analysis-based classification approach of [83],
as we achieved a sim ilar level of classification perform ance using just a single gene instead of 26. In addition, six
of the genes identified using the present m ethods are
mentioned as high-class discrimination genes in [20].
These six genes are OBF-1, CD24, MLCK, KIAA0867,
SMARCA4, and cDNA wg66 h09. Indeed, our rules
induced by each of the six genes are well in accordance
with the outcomes presented in [20], demonstrating that
these genes are highly expressed in ALL, moderately
expressed in MLL, and expressed at a low level in AML.

T able 14: Com par ison of best classificat ion accur acy for t he Leukem ia dat aset 2

Met hods (feat ur e select ion + classificat ion)

#Select ed genes

#Cor r ect ly classified sam ples (accur acy)

Rule-based classifier

α depended degree + decision rules [this work]

1

14 (93.33%)

yes

HykGene + k-NNs, SVMs, C4.5, NB [85]

26

100%f

noi

signal to noise ratios + k-NNs [20]

40

95%g

no

100

9 (90%)h

fLOOCV

result in a total of 72 samples.
in a total of 57 training samples.
hIn [20], only 3 of 8 AML testing samples in the dataset were mentioned. Thus, their test set contained 10 rather than 15 samples.
iExcept for C4.5, all the others are not rule-based classifiers.
gLOOCV result
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In summ ary, we h ave iden tified som e im portant genes
that not on ly possess potent classification ability but also
are closely associated with th e pathogenesis of specific or
general can cers in every dataset. In the Leukem ia dataset
1, significant genes such as Zyxin an d MGST1, frequen tly
identified by previous researchers, were also iden tified in
the presen t study. At the same tim e, we selected some
genes rarely identified by other m eth ods (e.g., TCRA,
KIAA0159, and MB-1), wh ich h ave been proven to correlate directly or in directly with AML-ALL class prediction .
Our results dem on strate that th e genes with excellen t performance in AML-ALL classification are n ot only the
m arkers of hematopoietic lin eage, but also related to gen eral cancer pathogen esis. Therefore, th e gen es we have
identified, wh ich are useful for AML-ALL classification , are
also in dicators of cancer pathogen esis and ph arm acology.
Th is is con sisten t with the conclusion of Golub et al. [2].
In the Lung Can cer dataset, we succeeded in identifying
h igh ly discrimin ative genes (e.g., CALB2, HAS1, and
ANXA8) im plicated in the pathogen esis of MPM, ADCA,
or oth er tum ors. In the Prostate Can cer dataset, we identified som e im portant genes with significant biological relevance, such as TMSB15A, PEDF, h epsin , KIAA0977, and
S100A4. In particular, hepsin , which has the h igh est
depended degree, h as been reported to have sign ificant
involvemen t in the path ogenesis of prostate cancer. In th e
Breast Can cer dataset, TSPYL5 was regarded as th e m ost
valuable prognostic m arker by our m eth ods and by the
correlation -based approach used in [19]. In th e Leukem ia
dataset 2, we iden tified OBF-1 an d others, wh ich excellently separate ALL, MLL, an d AML. Overall, the m ajority
of genes relevant to tumors encode protein s function ing
in cell growth, motility an d differen tiation , apoptosis,
an giogenesis, m etabolism , chrom osom al rearrangem ent
an d tran slocation , and imm un e reaction s.

Discussion
Microarray-based cancerous gene classification is a particular classification problem : the quan tity of features
(genes) greatly exceeds th e n um ber of instances (sam ples). As th e m ajority of features are redundan t for the
classification task, feature selection is of vital importance.
At the sam e tim e, th e discovery of importan t gen e m arkers
relevant to can cer rem ains a sign ifican t task. To this end,
we proposed a method of feature selection based on the
depended degree of attributes by classes, by which we
screened sin gle or double in form ative genes for classification. We built classifiers on th e basis of the decision rules
arising from th ese gen es or gene pairs. Using just a sm all
n um ber of features, we gained high-quality solutions to
classification problem s in the analysis of high -dim ensional gene expression data.
In general, our approach has advan tages over oth er methods. For exam ple, our m eth ods are based on rules. In con -

http://www.biomedcentral.com/1755-8794/2/64

trast to non-rule-based m ethods (e.g., SVMs, ANNs, GAs,
k-NNs and NB) rule-based m ethods are understandable
and logical, so that biologists and clinicians are m ore
inclined to adopt them. More importantly, as we utilize
very few genes (one or two) to construct classification
rules, the derived classifiers are quite simple and easily
understood. Hence, our rule-based m ethod has an advantage over other rule-based m ethods that involve m ore
com plicated rules.
Our work is consistent with the opinion expressed in
[86,87]: sim ple approaches perform well in microarraybased cancer prediction. This opinion is supportive of the
principle of Occam 's razor. It is not strange that single or
double genes can result in accurate classification of cancer, as the single genes or gene pairs m ight be the potential
biom arkers of cancer [17]. In contrast, when complex prediction models achieve highly accurate prediction rates
using a large num ber of genes, it is difficult to assess which
genes are the significant biomarkers of cancer. In fact,
molecular classification of cancer is a specific classification problem, as it incorporates essential double im plications: classification and identifying biomarkers of cancer.
Although accurate classification must be guaranteed, the
detection of biom arkers is also im portant, som etimes
even m ore so than accuracy; otherwise, the (accurate) classification results have only limited significance. Because
sim ple classification m odels may be advantageous in
finding important biomarkers with a high classification
accuracy, it is worthwhile applying simple prediction
approaches rather than com plex m ethods for the m olecular classification of cancer. Furtherm ore, it is better to utilize sim ple rule-based classification m ethods because of
their interpretability.
It should be noted that because we only verified th e classification accuracy using one independent test set for
every dataset, the stability of the classifier was not
assessed. That is, if the different training and test sets are
chosen, the classification results m aybe vary, although not
necessarily significantly deviate from our estim ates. Therefore, the present classification accuracies only roughly
reflect the quality of our classifiers. One m ore un biased
estim ate should be based on the average of the results
obtained by repeating the partition of sam ples between
training and test set m any times, which is tim e con sum ing
for our m ethods.

Conclusion
Our m icroarray-based cancer classification m ethods are
sim ple and interpretable relative to m ost other
approaches, since our classifiers are based on decision
rules, and the decision rules are based on single or double
genes. We dem onstrated the efficacy of our m ethods by
their application to several well-known gene expression
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datasets. In th ese datasets, our m ethods identified the single gen es or gene pairs that perform well in distinguishing
differen t classes of cancer. Moreover, a large proportion of
the genes screened by our m ethods m ay have biological
relevance to m alignan cy or cell type, m eaning that they
can be regarded as can didate biom arkers of can cer.
Gen erally speakin g, sim ple classification m odels are capable of givin g good performan ce in m ost classification
problem s, in cludin g th e m olecular classification of cancer, if a small n um ber of features are correctly selected
[6,12,14,88,89]. The present results len d support to th is
n otion. On e recom men ded follow-up study is to com bine
our methods with other established m ach ine-learning
algorithm s to address the problem of m olecular classification of cancer.
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